Non Small Cell Lung Cancer

ChromaCode partners with the Medical College of Georgia on NSCLC assay validation

By LabPulse.com staff writers

ChromaCode announced a partnership with the Medical College of Georgia to test the analytical and clinical performance of ChromaCode's HDPCR non-small cell lung cancer (NSCLC) biomarker assay.

March 21, 2024

Boehringer Ingelheim, Thermo Fisher to collaborate on CDx development for NSCLC

By LabPulse.com staff writers

Boehringer Ingelheim and Thermo Fisher have formed a partnership to develop companion diagnostic (CDx) tests for identifying patients with non-small cell lung cancer (NSCLC) with specific genomic mutations who may benefit from targeted therapies.

October 19, 2023

Guardant 360 CDx receives approval in Japan for NSCLC

By LabPulse.com staff writers

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved the Guardant360 CDx liquid biopsy test as a companion diagnostic for select patients with HER2-mutant NSCLC who are eligible for treatment with the antibody drug conjugate Enhertu.

September 7, 2023

Roche’s Alecensa improves survival in postsurgery lung cancer patients in late-phase trial

By Nick Paul Taylor

Roche’s Alecensa has improved disease-free survival in non-small cell lung cancer patients, positioning the Swiss drugmaker to apply to expand the product label.

September 8, 2023

Lunit to present results of AI-based immunotherapy predictive test study at WCLC 2023

By LabPulse.com staff writers

Lunit announced the presentation of data from a collaborative study on the use of the Lunit SCOPE IO test to predict immunotherapy treatment outcomes in lung cancer at the 2023 World Conference on Lung Cancer (WCLC 2023).

August 28, 2023

Amoy Diagnostics, AstraZeneca partner on CDx for lung cancer therapy

By LabPulse.com staff writers

This agreement is the latest in ongoing collaborations to develop and commercialize AmoyDx assays for companion diagnostic use with AstraZeneca's prostate, breast, and ovarian cancer therapies.

August 16, 2023

ChromaCode starts early-access launch of lung cancer variant test

By Nick Paul Taylor

The test is designed to address diagnostic problems that prevent patients from undergoing timely cancer biomarker testing and receiving targeted therapies.

August 15, 2023

Illumina inks deal to sell Pillar Biosciences’ cancer assays

By Nick Paul Taylor

Pillar, which has partnerships with Beckman Coulter Life Sciences and Labcorp, designed its NSCLC and CRC panel to run on the Illumina MiSeq Dx instrument. The instrument is a next-generation sequencing (NGS) platform for in vitro diagnostic testing.

July 26, 2023

Single-cell RNA sequencing data reveals T cells linked to cancer immunotherapy resistance

By Nick Paul Taylor

Scientists at the University of Texas MD Anderson Cancer Center have provided a new explanation for why checkpoint inhibitors are ineffective in some patients.

May 30, 2023

Cancer patients’ molecular testing, treatment varies across oncology practices in study

By Elissa Wolfson

Access to molecular testing and targeted therapy for non-small cell lung cancer and colorectal cancer patients varies across oncology practices.

April 28, 2023

Foundation Medicine to collaborate with Bristol Myers Squibb on companion diagnostic for solid tumors

By LabPulse.com staff writers

The FoundationOne CDx test would be used in identifying patients likely to respond to treatment with repotrectinib if both the treatment and the test are approved.

April 11, 2023

Foresight Diagnostics, Memorial Sloan Kettering Cancer Center to present study data on MRD monitoring at AACR

By LabPulse.com staff writers

In the study, the Foresight Solid Tumor Recurrence test achieved an LOD95 of less than one part per million in the majority of plasma samples analyzed, and was almost twice as sensitive as a first-generation ctDNA MRD approach.

April 4, 2023

Page 1 of 5

Next Page